CTRI/2011/12/002263招募中未知
An open, randomised, prospective study to evaluate the efficacy of pulse oral versus daily Calcitriol therapy for controlling secondary hyperparathyroidism in pre-dialysis CKD patients - A pilot study.
试验速览
- 阶段
- 未知
- 状态
- 招募中
- 发起方
- AIIMS
- 入组人数
- 50
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •1.Adults ( >18 years)
- •2.Both male and females
- •3.CKD Stage 3 (eGFR 30-59 ml/min/1.73 m2)
- •4.CKD Stage 4 (eGFR 15-29 ml/min/1.73 m2)
- •5.iPTH > 110 pg/ml (CKD-3)
- •6.iPTH > 150 pg/ml (CKD-4)
- •7.S. Calcium < 10.5 mg/dl
- •8.S.Phosphate < 4.6 mg/dl
- •9.Informed consent
排除标准
- •1.Pregnant or lactating females
- •2.Female patients unwilling for birth control
- •3.Evidence of cancer or active infections
- •4.Impaired LFT (SGPT >2times Upper limit normal)
- •5.Receiving any form of Vitamin D or cinacalcet within 4 weeks prior to screening
- •6.Receiving bisphosphonate/calcitonin within previous 12 months
- •7.History of prior transplant
- •8.Any active alcohol/drug dependence or abuse
- •9.On steroids > 30 days within previous 6 month
- •10.Previous parathyroidectomy
研究者
相似试验
进行中（未招募）
4 期
Study to evaluate the efficacy and safety of salmon protein hydrolyate in whey protein isolate powder to improve hemoglobin and serum ferritin in anaemic patientsCTRI/2014/02/004433Hofseth Biocare AS48
尚未招募
4 期
A study to determine effects of magnesiumsulphate with Bupivacaine hydrochloride in spinal anaesthesia.CTRI/2024/02/062867Anupama Kumari
已完成
不适用
The effects of adjuvant Tualang honey therapy on disease activity markers in systemic lupus erythematosus patientssystemic lupus erythematosusACTRN12611000074998School of Medical Sciences, Universiti Sains Malaysia60
进行中（未招募）
1 期
A randomised, open label, prospective study to assess two different therapeutic strategies following first treatment failure in HIV-1 infected subjects. ‘The First Failure Study’ : ‘FAST’ - The First Failure StudyHIVEUCTR2009-011816-39-GBImperial College London44
进行中（未招募）
不适用
Safety clinical trial with depigmented and polymerized allergenic extracts of a pollen combination: Depigoid 50% Grasses/50% Olea europaea (2000DPP/ml) or Depigoid 50% Grasses/50% Parietaria judaica (2000DPP/ml).Allergic rhinitis or rhinojunctivitis, with or without seasonal asthma to more than one of the following pollens: Grasses, Olea europaea and Parietaria judaica.MedDRA version: 15.0Level: LLTClassification code 10036019Term: Pollen allergySystem Organ Class: 10021428 - Immune system disordersEUCTR2012-001699-12-ESaboratorios LETI, S.L.